Biomedicine / 政策跟进
Peptide easing remains unannounced; pharmacy group details its proposal
The peptide-policy report shared by unusual_whales is not an operative drug rule. On October 9, the Alliance for Pharmacy Compounding said the reported plan remained unannounced, with no announced timeline and details subject to change.
APC says it met the FDA twice to seek interim enforcement discretion for state-licensed compounding pharmacies. Its proposed conditions include stronger patient disclosures, serious-adverse-event reporting and collection of usage data. These are an industry group’s requests, not established FDA requirements.
Advocacy, a formal change in enforcement and approval for a specific treatment are separate questions. This review obtained neither a new effective policy nor an applicable peptide list, and establishes no product’s safety or efficacy.
Sources and further reading
Edited report
Selected through a verified followed account: @unusual_whales.